| Repotrectinib studied in …STUDIED_INderived14 of 14show fewer |
|---|
| → studied in | NCT04094610Phase 1/Phase 2 · recruiting A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations · 14 trials list this drug (8 active) | — | — | Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06140836Phase 3 · active not recruiting A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) · 14 trials list this drug (8 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06315010Phase 2 · recruiting Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis · 14 trials list this drug (8 active) | — | — | Brain Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07755826recruiting Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan · 14 trials list this drug (8 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06552234Phase 2 · recruiting Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC · 14 trials list this drug (8 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05004116Phase 1/Phase 2 · recruiting A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer · 14 trials list this drug (8 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03093116Phase 1/Phase 2 · recruiting A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements · 14 trials list this drug (8 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07599007not yet recruiting Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion · 14 trials list this drug (8 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06408168Phase 2 · terminated Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) · 14 trials list this drug (8 active) | — | — | Invasive Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06352528Phase 1 · completed A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment · 14 trials list this drug (8 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05828303Phase 1 · withdrawn A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors · 14 trials list this drug (8 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04772235Phase 1 · unknown Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients · 14 trials list this drug (8 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05071183Phase 1/Phase 2 · terminated A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors · 14 trials list this drug (8 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05828277Phase 1 · withdrawn A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients · 14 trials list this drug (8 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |